About
Adialante builds compact, diagnostic-grade MRI systems delivered through mobile imaging clinics for private practices and medical sites, starting with pre-biopsy prostate imaging for urology clinics. Its differentiation is redesigned physics, algorithms, and hardware that make MRI quieter, lighter, more accessible, and deployable without a shielded room, construction, or capital purchase.
Market
Adialante competes in diagnostic medical imaging, particularly decentralized outpatient MRI and cancer-screening access, by bringing a diagnostic-grade mobile MRI unit to specialty practices instead of requiring hospital-style capital infrastructure. Its differentiation is a clinic-capex-light, per-scan operating model combined with compact, quieter, lighter MRI hardware and proprietary physics, while competitors range from portable brain MRI and prostate-intervention systems to conventional mobile-imaging and whole-body MRI providers.
Adialante targets private and independent outpatient specialty clinics—initially urology practices—that need diagnostic-grade MRI but lack the capital, space, construction capacity, or technical infrastructure for a conventional scanner. The likely buyers are clinic owners, operators, and specialty physicians; the per-scan model lets practices schedule patients, collect insurance reimbursement, and retain imaging margin.
At a Glance
Problem
Adialante targets the access and delay problem in diagnostic MRI. Conventional scanners cost millions, take months to install, require specialized infrastructure, and are concentrated in hospitals, leaving many clinics unable to offer MRI and creating weeks-long waits. The clinical and economic pain is especially acute in prostate cancer: more than one million men each year require an MRI before prostate biopsy, yet most urology practices cannot provide the scan in-house. Delayed imaging can mean delayed diagnosis, while clinics lose the opportunity to retain the referral and associated reimbursement.
Product / Service
Adialante is developing compact, diagnostic-grade whole-body MRI systems delivered as a mobile imaging clinic. Rather than selling the equipment, it plans to own and operate MRI units in trailers, bring them to medical practices, manage scanning operations, and improve the system’s AI software over time. The system is designed to use substantially less hardware, be lighter, quieter, shorter, and require no specialized infrastructure.
Clinics pay a flat per-scan fee instead of making a multimillion-dollar capital purchase or undertaking construction. They schedule patients on-site, collect the insurance reimbursement, and retain the margin, while patients can receive imaging in hours rather than being referred to a hospital and waiting months. Adialante’s initial use case is pre-biopsy prostate imaging, with planned expansion into renal, breast, and brain scanning.
Market
Adialante competes in portable and mobile diagnostic MRI, with an initial focus on decentralized cancer screening and point-of-care imaging. Its closest differentiated competitors include Hyperfine, whose FDA-cleared Swoop system is a portable brain MRI, and Promaxo, whose FDA-cleared platform focuses on MRI-guided prostate procedures. Adialante’s intended distinction is a mobile, diagnostic-grade, whole-body platform operated as a service rather than a scanner sold to each clinic; conventional hospital MRI remains the incumbent alternative.
The company is an early commercial-stage medtech startup rather than an established revenue business. Its public materials say first clinics are planned to go live in Q4 2026, while also reporting that a first system is scanning. By July 2026, Adialante reported 11 clinics reserving slots and $19.75 million in signed letters of intent, alongside deposits from early customers; the cited materials do not report recognized revenue. The commitments indicate meaningful demand validation, but deployment, regulatory commercialization, utilization, and recurring revenue remain ahead of the company.
Founders & Leadership
Funding History
America’s Seed Fund
National Science Foundation (NSF SBIR)
Y Combinator
Recent News
Twin Cities Business reported that Adialante has created a mobile imaging clinic for cancer screening. The company reported $19.5 million in letters of intent and 11 clinics signed up, while moving to Silicon Valley and preparing to scale its University of Minnesota-born MRI technology.
Panacea announced that Adialante partnered with it for FDA regulatory support. Panacea says its AI-enabled workflows and regulatory expertise shortened Adialante's timeline and reduced costs, while fixed milestone-based pricing provided cost certainty.
Tracxn's 2026 company profile identifies Adialante as a Minneapolis-based seed company developing affordable, compact, silent MRI systems. It reports $500,000 raised across two rounds, with the latest round classified as a 2026 seed round.
A YC Spring 2026 profile described Adialante's mobile MRI as an imaging clinic on wheels that requires no equipment purchase or specialized infrastructure. The model is based on a flat per-scan fee so medical sites can offer MRI-based cancer screening.
The Silicon Valley Post covered Adialante's compact, mobile whole-body MRI system, which is designed for clinics unable to afford or house conventional scanners. The company reported $19.75 million in letters of intent, $30,000 in deposits, six clinics signed up, and a first system already scanning; its initial focus is prostate cancer.
Adialante's official Y Combinator launch post introduced its compact, mobile whole-body MRI offering and reported $12.75 million in letters of intent, $30,000 in deposits, six clinics signed up, and an assembled MRI system. The company said the first system would be scanning by Demo Day.
The NSF America's Seed Fund's active-awardee directory listed ADIALANTE L.L.C. under Phase II awards with identifier MN 2449556 and an award amount of $1,186,778. This is an official funding record rather than a standalone company press release.
Active Roles
3Business Model
Adialante plans to own and operate its MRI hardware in mobile trailers and charge clinics a flat per-scan fee rather than sell machines; clinics can collect insurance reimbursement and earn a profit. This creates recurring scan revenue for Adialante while giving medical sites MRI access without a capital purchase.